RADIUS HEALTH, INC. (NASDAQ:RDUS) Files An 8-K Regulation FD Disclosure

RADIUS HEALTH, INC. (NASDAQ:RDUS) Files An 8-K Regulation FD Disclosure
Item 9.01Regulation FD Disclosure.

Story continues below

Attached hereto as Exhibit 99.1 and incorporated herein by reference is a corporate update presentation to be utilized by Radius Health, Inc. at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, California.

The information contained in Item 9.01 of this Form 8-K (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly provided by specific reference in such a filing.

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits

Radius Health, Inc. Exhibit
EX-99.1 2 rdus-ex991_233.htm EX-99.1 rdus-ex991_233.pptx.htm Radius Health (RDUS) JP Morgan Healthcare Conference JANUARY 7,…
To view the full exhibit click here

About RADIUS HEALTH, INC. (NASDAQ:RDUS)

Radius Health, Inc. is a biopharmaceutical company focused on developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. Its product candidate, the investigational drug abaloparatide for subcutaneous injection, has completed Phase III development for use in the reduction of fracture risk in postmenopausal women with osteoporosis. Its clinical pipeline also includes an investigational abaloparatide transdermal patch for use in osteoporosis and the investigational drug RAD1901 for use in hormone-driven and hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women. Its preclinical pipeline includes RAD140, a non-steroidal, selective androgen receptor modulator (SARM) under investigation for use in cancer.

An ad to help with our costs